Disruption of p53-p21/WAF1 cell cycle pathway contributes to progression and worse clinical outcome of hepatocellular carcinoma

Oncology Reports

Volumn 12, Issue 1, 2004, Pages 25-31

  Lee, Terence Kin Wah ^a   Man, Kwan ^a   Poon, Ronnie Tung Ping ^a   Lo, Chung Mau ^a   Ng, Irene Oi Lin ^a   Fan, Sheung Tat ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Hepatocellular carcinoma; p21 WAF1; p53; Progression; Proliferating cell nuclear antigen

Indexed keywords

CDKN1A PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE;

ARTICLE; CELL CYCLE; DISEASE COURSE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TUMOR; MORTALITY; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DISEASE PROGRESSION; GENES, P53; HEPATECTOMY; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; PROLIFERATING CELL NUCLEAR ANTIGEN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 21644447666     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.12.1.25     Document Type: Article

References (29)

1. Zambetti GP, Bargonetti J, Walker K, Prives C and Levine AJ: Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes Dev 6: 1143-1152, 1992.
2. El-Deiry WS, Tokino T, Velculescu VE, et al: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993. (Pubitemid 23346378)
3. Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816, 1993. (Pubitemid 23346377)
4. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R and Beach D: p21 is a universal inhibitor of cyclin kinases. Nature 366: 701-704, 1993. (Pubitemid 24036020)
5. Zhang W, Grasso L, McClain CD, et al: p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res 55: 668-674, 1995.
6. Hollstein M, Sidransky D, Vogelstein B and Harris CC: p53 mutations in human cancers. Science 253: 49-53, 1991. (Pubitemid 21917115)
7. Ng IOL, Chung LP, Tsang SW, Lam CL, Lai EC, Fan ST and Ng M: p53 gene mutation spectrum in hepatocellular carcinomas in Hong Kong Chinese. Oncogene 9: 985-990, 1994. (Pubitemid 24065942)
8. Itoh T, Shiro T, Seki T, Nakagawa T, Wakabayashi M, Inoue K and Okamura A: Relationship between p53 overexpression and the proliferative activity in hepatocellular carcinoma. Int J Mol Med 6: 137-142, 2000.
9. Mise K, Tashiro S, Yogita S, et al: Assessment of the biological malignancy of hepatocellular carcinoma: relationship to clinicopathological factors and prognosis. Clin Cancer Res 4: 1475-1482, 1998. (Pubitemid 28265231)
10. Shi YZ, Hui AM, Takayama T, Li X, Cui X and Makuuchi M: Reduced p21(WAF1/CIP1) protein expression is predominantly related to altered p53 in hepatocellular carcinomas. Br J Cancer 83: 50-55, 2000. (Pubitemid 30352716)
11. Su Q, Schroder CH, Otto G and Bannasch P: Overexpression of p53 protein is not directly related to hepatitis B x protein expression and is associated with neoplastic progression in hepatocellular carcinomas rather than hepatic preneoplasia. Mutat Res 462: 365-380, 2000. (Pubitemid 30190242)
12. Edmondson HA and Steiner PE: Primary carcinoma of liver: a study of 100 cases among 48,900 necropsies. Cancer 7: 462-503, 1954.
13. Sobin LH and Wittekind CH (eds): UICC International Union Against Cancer: TNM Classification of Malignant Tumours. 6th edition. Wiley-Liss, New York, 2002.
14. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G and Oberhuber G: Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 60: 4693-4696, 2000.
15. Ando T, Kawabe T, Ohara H, Ducommun B, Itoh M and Okamoto T: Involvement of the interaction between p21 and proliferating cell nuclear antigen for the maintenance of G2/M arrest after DNA damage. J Biol Chem 276: 42971-42977, 2001.
16. El-Deiry WS, Harper JW, O'Connor PM, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169-1174, 1994.
17. Wilson JW, Deed RW, Inoue T, et al: Expression of Id helix-loop-helix proteins in colorectal adenocarcinoma correlates with p53 expression and mitotic index. Cancer Res 61: 8803-8810, 2001. (Pubitemid 34013894)
18. Chen X, Cheung ST, So S, et al: Gene expression patterns in human liver cancers. Mol Biol Cell 13: 1929-1939, 2002. (Pubitemid 34651483)
19. Marchetti A, Doglioni C, Barbareschi M, et al: p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. Oncogene 12: 1319-1324, 1996.
20. El-Deiry WS, Tokino T, Waldman T, et al: Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 55: 2910-2919, 1995.
21. Tron VA, Tang L, Yong WP and Trotter MJ: Differentiation-associated overexpression of the cyclin-dependent kinase inhibitor p21waf-1 in human cutaneous squamous cell carcinoma. Am J Pathol 149: 1139-1146, 1996. (Pubitemid 26337233)
22. Qin LF, Ng IOL, Fan ST and Ng M: p21/WAF1, p53 and PCNA expression and p53 mutation status in hepatocellular carcinoma. Int J Cancer 79: 424-428, 1998. (Pubitemid 28359743)
23. Furutani M, Arii S, Tanaka H, et al: Decreased expression and rare somatic mutation of the CIP1/WAF1 gene in human hepatocellular carcinoma. Cancer Lett 111: 191-197, 1997. (Pubitemid 27068236)
24. Waga S and Stillman B: Cyclin-dependent kinase inhibitor p21 modulates the DNA primer-template recognition complex. Mol Cell Biol 18: 4177-4187, 1998. (Pubitemid 28287941)
25. Chuang LS, Ian HI, Koh TW, Ng HH, Xu G and Li BF: Human DNA-(cytosine-5) methyltransferase-PCNA complex as a target for p21WAF1. Science 277: 1996-2000, 1997. (Pubitemid 27449142)
26. Ng IOL, Lai EC, Fan ST, Ng M, Chan AS and So MK: Prognostic significance of proliferating cell nuclear antigen expression in hepatocellular carcinoma. Cancer 73: 2268-2274, 1994. (Pubitemid 24129107)
27. Qin LF and Ng IOL: Exogenous expression of p21(WAF1/CIP1) exerts cell growth inhibition and enhances sensitivity to cisplatin in hepatoma cells. Cancer Lett 172: 7-15, 2001. (Pubitemid 32823467)
28. Sugibayashi R, Kiguchi Y, Shimizu T, Suzuki T, Hamada H and Takeda K: Up-regulation of p21(WAF1/CIP1) levels leads to growth suppression of prostate cancer cell lines. Anticancer Res 22 (2A): 713-719, 2002. (Pubitemid 34475219)
29. Han Z, Wei W, Dunaway S, et al: Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin. J Biol Chem 277: 17154-17160, 2002. (Pubitemid 34967748)